Gemzar "Double-Patenting" Case Has Broad Implications For Industry Pipeline
Executive SummaryEli Lilly & Co. has the backing of the pharmaceutical and biotech industries in its effort to get an appeals court to reverse its ruling that the company’s Gemzar (gemcitabine) patent is invalid.
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.